Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn

Table of Contents

March 01, 1994; Volume 22,Issue 2
  • You have access
    Disposition of the angiotensin II receptor antagonist L-158,809 in rats and rhesus monkeys.
    A E Colletti and P A Krieter
    Drug Metabolism and Disposition March 1994, 22 (2) 183-188;
  • You have access
    Use of rat and human in vitro systems to assess the effectiveness and enzymology of deoxyguanine analogs as prodrugs of an antiviral agent.
    A W Harrell, S M Wheeler, P East, S E Clarke and R J Chenery
    Drug Metabolism and Disposition March 1994, 22 (2) 189-193;
  • You have access
    Absorption and disposition of SDZ IMM 125, a new cyclosporine derivative, in rats after single and repeated administration.
    A Bruelisauer, R Kawai, P Misslin and M Lemaire
    Drug Metabolism and Disposition March 1994, 22 (2) 194-199;
  • You have access
    Metabolism of 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2 (1H)-one (L-696,229), an HIV-1 reverse transcriptase inhibitor, by rat liver slices and in humans.
    S K Balani, L R Kauffman, B H Arison, T V Olah, M E Goldman, S L Varga, J A O'Brien, H G Ramjit, C S Rooney and J M Hoffman
    Drug Metabolism and Disposition March 1994, 22 (2) 200-205;
  • You have access
    Solvolytic formation of 1,2-dichloro-3,4-epoxybutane from butadiene monoxide under physiological conditions.
    X Cheng, C Maniglier-Poulet, D Ross and J A Ruth
    Drug Metabolism and Disposition March 1994, 22 (2) 206-210;
  • You have access
    Disposition of [14C]acitretin in humans following oral administration.
    F Rubio, B K Jensen, L Henderson, W A Garland, A Szuna and C Town
    Drug Metabolism and Disposition March 1994, 22 (2) 211-215;
  • You have access
    Dispositional characteristics of a tyrosine kinase inhibitor (RG 14620) in rats and rabbits following intravenous administration or dermal application.
    V K Khetarpal, P M Markham and J A Ziemniak
    Drug Metabolism and Disposition March 1994, 22 (2) 216-223;
  • You have access
    Bile flow but not enterohepatic recirculation influences the pharmacokinetics of ranitidine in the rat.
    A B Suttle and K L Brouwer
    Drug Metabolism and Disposition March 1994, 22 (2) 224-232;
  • You have access
    The pharmacokinetics of 1,3-di(4-imidazolino-2-methoxyphenoxy) propane.lactate (DMP.lactate), a new agent against opportunistic infections, in male beagle dogs.
    I Bekersky, R J Puhl, G Hanson and S Mong
    Drug Metabolism and Disposition March 1994, 22 (2) 233-236;
  • You have access
    Metabolic kinetics of pseudoracemic propranolol in human liver microsomes. Enantioselectivity and quinidine inhibition.
    P H Marathe, D D Shen and W L Nelson
    Drug Metabolism and Disposition March 1994, 22 (2) 237-247;
  • You have access
    Induction and regulation of CYP2E1 in murine liver after acute and chronic acetone administration.
    P G Forkert, Z M Redza, S Mangos, S S Park and S P Tam
    Drug Metabolism and Disposition March 1994, 22 (2) 248-253;
  • You have access
    Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat.
    R W Klecker, C A Jamis-Dow, M J Egorin, K Erkmen, R J Parker, R Stevens and J M Collins
    Drug Metabolism and Disposition March 1994, 22 (2) 254-258;
  • You have access
    Metabolism of isbufylline in humans. Isolation, identification, and synthesis of plasma and urine metabolites.
    O Agostini, G Bonacchi, G Coppini, E Toja, A Triolo, S Manzini, G Pieraccini and G Moneti
    Drug Metabolism and Disposition March 1994, 22 (2) 259-268;
  • You have access
    The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron.
    V Fischer, A E Vickers, F Heitz, S Mahadevan, J P Baldeck, P Minery and R Tynes
    Drug Metabolism and Disposition March 1994, 22 (2) 269-274;
  • You have access
    Pharmacokinetic study of p-chloronitrobenzene in rat.
    T Yoshida
    Drug Metabolism and Disposition March 1994, 22 (2) 275-280;
  • You have access
    In vitro metabolism of L-696,229, an HIV-1 reverse transcriptase inhibitor in rats and humans. Hepatic and extrahepatic metabolism and identification of enzymes involved in the hepatic metabolism.
    T Prueksaritanont, L M Dwyer, S K Balani and A D Theoharides
    Drug Metabolism and Disposition March 1994, 22 (2) 281-288;
  • You have access
    Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid.
    L Dalgaard, R K Hjortkjaer, B Regnier and L Nordholm
    Drug Metabolism and Disposition March 1994, 22 (2) 289-293;
  • You have access
    Pharmacokinetics of SM-10888 and its metabolites depending on their physicochemical properties.
    M Yabuki, T Mine, K Iba, I Nakatsuka and A Yoshitake
    Drug Metabolism and Disposition March 1994, 22 (2) 294-297;
  • You have access
    Milacemide metabolism in rat liver and brain slices by solids NMR.
    J R Garbow, W P Ridley, V Bork, Y Pan and J Schaefer
    Drug Metabolism and Disposition March 1994, 22 (2) 298-303;
  • You have access
    Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma.
    R F Mayol, C A Cole, G M Luke, K L Colson and E H Kerns
    Drug Metabolism and Disposition March 1994, 22 (2) 304-311;
  • You have access
    Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice.
    Y Kido, A R Khokhar, M Yoshida, G W Thai and Z H Siddik
    Drug Metabolism and Disposition March 1994, 22 (2) 312-317;
  • You have access
    Salicylate inhibits the renal transport of inorganic sulfate in rat membrane vesicle preparations.
    I M Darling, M L Mammarella, Q Chen and M E Morris
    Drug Metabolism and Disposition March 1994, 22 (2) 318-323;
  • You have access
    NADPH-dependent, regioselective S-oxidation of a thionosulfur- and thioether-containing xenobiotic, diethyldithiocarbamate methyl ester by rat liver microsomes.
    A Madan and M D Faiman
    Drug Metabolism and Disposition March 1994, 22 (2) 324-330;
  • You have access
    Cytochrome P-450-dependent biotransformation of 2-acetylaminofluorene in cell-free preparations of human embryonic hepatic, adrenal, renal, pulmonary, and cardiac tissues.
    M J Namkung, H L Yang and M R Juchau
    Drug Metabolism and Disposition March 1994, 22 (2) 331-337;
  • You have access
    NG-nitro-L-arginine is not involved in enterohepatic cycling in rats.
    V K Piotrovskij, Z Kállay, J Horecký, T Trnovec, G Raberger and K Krejcy
    Drug Metabolism and Disposition March 1994, 22 (2) 338-339;
Back to top
PreviousNext

In this issue

Drug Metabolism and Disposition
Vol. 22, Issue 2
1 Mar 1994
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
  • Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes
  • DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
  • In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model
  • THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics